Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413853 | 0.82 | EIF4A3 (0.38) | ALDH1A1SMN1; SMN2TYRERN1TSHR | |
| SCHEMBL13049121 | 0.82 | GRIA1 (0.42) | ALDH1A1SMN1; SMN2TYRERN1TSHR | |
| SCHEMBL13652480 | 0.79 | TDP1 (0.34) | ALDH1A1SMN1; SMN2TYRERN1LMNA | |
| SCHEMBL5504159 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ERN1TSHRGRIA1 | |
| SCHEMBL12375394 | 0.79 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2ERN1TSHRGRIA1 | |
| SCHEMBL9945874 | 0.77 | LMNA (0.35) | ALDH1A1LMNA | |
| SCHEMBL25534375 | 0.75 | TYR (0.38) | ALDH1A1SMN1; SMN2TYRERN1TSHR | |
| SCHEMBL13588022 | 0.74 | GABRA1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL20642320 | 0.74 | EIF4A3 (0.37) | ALDH1A1LMNA | |
| SCHEMBL22302453 | 0.74 | TYR (0.43) | ALDH1A1SMN1; SMN2TYRERN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107743488-B | 2-oxo-1, 3, 8-triazaspiro [4.5] decan-3-yl ] carboxylic acid derivatives | 伊莱利利公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3310780-A1 | 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL]CARBOXYLIC ACID DERIVATIVES | Eli Lilly and Company (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9920056-B2 | 2-oxo-1,3,8-triazaspiro[4.5]decan-3-yl] carboxylic acid derivatives | ELI LILLY AND COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| CN-107743488-A | 2-oxo-1, 3, 8-triazaspiro [4.5] decan-3-yl ] carboxylic acid derivatives | 伊莱利利公司 | 2018-02-27 | — | — | CN | disclosed |
| US-20160368922-A1 | 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL] CARBOXYLIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2016-12-22 | — | — | US | disclosed |
| WO-2016205032-A1 | 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL] CARBOXYLIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368922-A1 | 2-OXO-1,3,8-TRIAZASPIRO[4.5]DECAN-3-YL] CARBOXYLIC ACID DERIVATIVES | SLC5A2, SLC5A1, GPR119 | ALDH1A1 131/4885SMN1; SMN2 2434/4885TYR 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.